All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What are the main advances in patient care that we are seeing with novel agents for leukemia? ASCO21

During the 2021 ASCO Annual Meeting, the ALL Hub spoke with Jorge Cortes, Augusta University, Augusta, US. We asked, What are the main advances in patient care that we are seeing with novel agents for leukemia?

What are the main advances in patient care that we are seeing with novel agents for leukemia?

Cortes begins by outlining two practice-changing trials and their encouraging response rates. The first being the ZUMA-3 (utilizing CAR T-cell therapy), and the second investigating lintuzumab regimes in adult Philadelphia chromosome-positive ALL patients. He goes on to review two further studies investigating inotuzumab and the value of assessing MRD in patients.

 

Share: